The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the U.S.

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...